Overview: Celtere RTU 20 Injection contains Trastuzumab Emtansine (20 mg) and is a prescription targeted anticancer medicine used in the treatment of HER2-positive breast cancer by delivering a cytotoxic agent directly to HER2-expressing tumor cells through antibody-drug conjugate technology. Key Benefits: – Combines targeted HER2 antibody with cytotoxic agent for precise action – Effective in HER2-positive breast cancer including metastatic disease – Ready-to-use formulation for convenient clinical infusion Composition: Trastuzumab Emtansine (20 mg) How It Works: Trastuzumab Emtansine is an antibody-drug conjugate that binds to the HER2 receptor on cancer cells, is internalized, and releases the cytotoxic agent DM1 to disrupt microtubule function, leading to cancer cell death. Usage Instructions: – Administer only under the supervision of qualified healthcare professionals via intravenous infusion – Follow prescribed dosage and schedule for optimal efficacy – Not for self-administration Side Effects: – Infusion-related reactions including fever, chills and nausea – Fatigue, headache, elevated liver enzymes – Thrombocytopenia and peripheral neuropathy in some patients Precautions: – Monitor liver function, blood counts and cardiac status before and during treatment – Not recommended during pregnancy or breastfeeding unless clearly advised by a physician – Inform your doctor of all current medications prior to infusion Storage Instructions: – Store refrigerated between 2-8°C, protect from light, do not freeze Manufacturer: Generic Pharmaceuticals Disclaimer: To be sold by retail on the prescription of a registered medical practitioner only.